Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cambridge Cognition Holdings PLC - Cambridge-based brain health assessment software provider - Wins £2.2 million contract for providing cognitive assessments and electronic diaries for a neurodegenerative disease trial.
Revenue from the contract is expected over the next two financial years, and is a follow-on sale from a £2.1 million contract announced by Cambridge in early February.
‘We are pleased to have further strengthened our relationship with this pharmaceutical customer that is committed to tackling neurodegenerative disease. Cambridge Cognition has a strong history of delivering cognitive assessments in the field, traditionally in clinics and now also at home,’ said Chief Executive Officer Matthew Stork.
Current stock price: 125.00 pence
12-month change: down 20%
Copyright 2022 Alliance News Limited. All Rights Reserved.